Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- About
OBIO 
Orchestra BioMed Holdings Inc. (OBIO)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
01/09/2026: OBIO (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
7 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $13.71
1 Year Target Price $13.71
| 4 | Strong Buy |
| 3 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -58.64% | Avg. Invested days 28 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 01/09/2026 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 273.29M USD | Price to earnings Ratio - | 1Y Target Price 13.71 |
Price to earnings Ratio - | 1Y Target Price 13.71 | ||
Volume (30-day avg) 7 | Beta 0.63 | 52 Weeks Range 2.20 - 6.16 | Updated Date 01/9/2026 |
52 Weeks Range 2.20 - 6.16 | Updated Date 01/9/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.8 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -2359.23% |
Management Effectiveness
Return on Assets (TTM) -52.21% | Return on Equity (TTM) -166.97% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 193504298 | Price to Sales(TTM) 96.98 |
Enterprise Value 193504298 | Price to Sales(TTM) 96.98 | ||
Enterprise Value to Revenue 68.67 | Enterprise Value to EBITDA -1.81 | Shares Outstanding 56464731 | Shares Floating 32528202 |
Shares Outstanding 56464731 | Shares Floating 32528202 | ||
Percent Insiders 20.58 | Percent Institutions 40.69 |
Upturn AI SWOT
Orchestra BioMed Holdings Inc.
Company Overview
History and Background
Orchestra BioMed Holdings Inc. was founded in 2014. The company has focused on developing and commercializing novel medical technologies, with a particular emphasis on cardiovascular and orthopedic applications. A significant milestone was its merger with the SPAC BioLife Acquisition Corp. in 2021, which allowed it to become a publicly traded entity.
Core Business Areas
- BioMedical Device Development: Orchestra BioMed is engaged in the development and commercialization of proprietary medical devices. The company aims to address unmet needs in various therapeutic areas through innovative technologies.
- Commercialization and Licensing: Orchestra BioMed also focuses on strategies for the commercialization of its developed technologies, which may include direct sales, partnerships, or licensing agreements.
Leadership and Structure
Information on Orchestra BioMed Holdings Inc.'s specific leadership team and detailed organizational structure would require real-time access to company filings and public disclosures, which is beyond the scope of this static analysis. Generally, publicly traded companies have a Board of Directors overseeing management, which includes a CEO, CFO, and other executive officers responsible for day-to-day operations and strategic direction.
Top Products and Market Share
Key Offerings
- BioOrchestrau2122 Platform: The BioOrchestrau2122 platform is a proprietary technology designed for localized drug delivery, particularly for the treatment of vascular diseases. Specific market share data or revenue figures for this platform are not publicly available as it is a development-stage technology. Competitors in localized drug delivery include companies developing drug-eluting stents and other localized therapeutic delivery systems.
- Cardiovascular Devices: The company is developing devices for cardiovascular applications, aiming to improve patient outcomes in areas like restenosis and thrombosis. Detailed market share or revenue for specific, pre-commercialized cardiovascular devices is not yet established. Competitors would include major cardiovascular device manufacturers.
- Orthopedic Devices: Orchestra BioMed is also exploring opportunities in the orthopedic space, potentially for bone healing or joint restoration. Specific product details and market share are not readily available for these early-stage initiatives. Competitors in the orthopedic device market are numerous and include large, established players.
Market Dynamics
Industry Overview
Orchestra BioMed operates within the highly competitive and innovative medical device and biotechnology sectors. These industries are characterized by significant research and development investment, regulatory hurdles (FDA approval), and a focus on unmet medical needs. The cardiovascular and orthopedic device markets are substantial and growing, driven by an aging population and increasing prevalence of chronic diseases.
Positioning
Orchestra BioMed's positioning is as an early-stage, innovation-driven company focused on developing novel technologies. Its competitive advantage lies in its proprietary platforms and scientific approach to addressing complex medical challenges. However, as a developmental-stage company, it faces challenges in commercialization and market penetration compared to established players.
Total Addressable Market (TAM)
The Total Addressable Market for Orchestra BioMed's potential product areas (cardiovascular, orthopedic, drug delivery) is in the tens of billions of dollars globally. The company's positioning is to capture a niche within these large markets with its specific technological innovations, but its current market share is effectively zero as it is pre-commercialization for most of its key technologies.
Upturn SWOT Analysis
Strengths
- Proprietary technology platforms (e.g., BioOrchestrau2122).
- Focus on addressing significant unmet medical needs.
- Potential for innovation and disruptive solutions.
Weaknesses
- Early-stage development; products are not yet commercialized.
- Reliance on significant R&D funding and future capital raises.
- Limited track record of commercial success.
- Regulatory approval risks.
Opportunities
- Growing demand for advanced medical devices.
- Strategic partnerships and licensing opportunities.
- Expansion into new therapeutic areas.
- Advancements in medical technology and material science.
Threats
- Intense competition from established medical device companies.
- Stringent regulatory requirements and lengthy approval processes.
- Unforeseen clinical trial outcomes.
- Changes in healthcare reimbursement policies.
- Technological obsolescence.
Competitors and Market Share
Key Competitors
- N/A (Pre-commercialization)
- N/A (Pre-commercialization)
Competitive Landscape
Orchestra BioMed faces a competitive landscape populated by large, established medical device companies and numerous smaller biotech firms. Its competitive advantages are its novel technologies, but it faces disadvantages in terms of established distribution channels, brand recognition, and financial resources compared to larger players. Success hinges on demonstrating superior efficacy and safety in clinical trials and securing strategic partnerships.
Growth Trajectory and Initiatives
Historical Growth: Historical growth for Orchestra BioMed has been characterized by scientific and technological development, rather than commercial sales growth. The company has focused on building its intellectual property portfolio and advancing its pipeline through preclinical and early clinical stages.
Future Projections: Future growth projections for Orchestra BioMed are speculative and dependent on the successful development, regulatory approval, and commercialization of its pipeline products. Analyst estimates, if available, would be contingent on clinical trial success and market adoption rates. Without specific analyst consensus, this remains qualitative.
Recent Initiatives: Recent initiatives likely include ongoing clinical trials for its lead product candidates, strategic collaborations, and efforts to secure further funding to advance its pipeline.
Summary
Orchestra BioMed Holdings Inc. is an early-stage biotechnology company focused on developing innovative medical devices in cardiovascular and orthopedic areas. Its strength lies in its proprietary technology platforms and potential to address significant unmet medical needs. However, it faces considerable weaknesses due to its pre-commercial status, reliance on R&D funding, and regulatory risks. The company needs to carefully navigate the competitive landscape, secure adequate funding, and successfully execute its clinical development and commercialization strategies to realize its potential.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company public filings (SEC)
- Financial news outlets
- Industry analysis reports
Disclaimers:
This analysis is based on publicly available information and general industry knowledge. It is not intended as investment advice. Specific numerical data, especially for financial metrics and market share, requires access to real-time, up-to-date financial reports and market research that are beyond the scope of this general overview.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Orchestra BioMed Holdings Inc.
Exchange NASDAQ | Headquaters New Hope, PA, United States | ||
IPO Launch date 2020-08-04 | Founder, Chairman of the Board of Directors & CEO Mr. David P. Hochman | ||
Sector Healthcare | Industry Biotechnology | Full time employees 70 | Website https://orchestrabiomed.com |
Full time employees 70 | Website https://orchestrabiomed.com | ||
Orchestra BioMed Holdings, Inc. operates as a biomedical company in the United States. The company's flagship product candidates include Atrioventricular Interval Modulation, a bioelectronic therapy candidate designed to immediately, substantially, and persistently lower blood pressure; and Virtue Sirolimus AngioInfusion Balloon for the treatment of atherosclerotic artery disease. It also develops Cardiac Neuromodulation Therapy for heart failure, or potential treatment of clinical indications; and CNT-HF, a bioelectronic product candidate that aims to reduce chronic sympathetic nervous system activity in heart failure. In addition, the company offers FreeHold devices and additional minimally invasive surgery enabling devices; and Pure-Vu system, a medical device to facilitate the cleansing of a poorly prepared gastrointestinal tract during colonoscopy and upper gastrointestinal endoscopy procedures. It has a collaboration agreement with Medtronic, Inc. for the development of AVIM therapy for the treatment of HTN in pacemaker-indicated patients; and a strategic collaboration with Terumo Corporation and Terumo Medical Corporation for the development and commercialization of Virtue SAB for the treatment of coronary and peripheral artery disease. Orchestra BioMed Holdings, Inc. was founded in 2018 and is headquartered in New Hope, Pennsylvania.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.